Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204785 | 0.91 | MAPT (0.38) | MCHR1NR2E1MAPTTP53POLB | |
| SCHEMBL2203664 | 0.90 | NR2E1 (0.43) | MCHR1NR2E1MAPTTP53POLB | |
| SCHEMBL2201384 | 0.89 | KDR (0.47) | MCHR1NR2E1ROCK2KDR | |
| SCHEMBL1408435 | 0.87 | MCHR1 (0.44) | MCHR1MAPTMEN1KMT2ATP53 | |
| SCHEMBL2200252 | 0.85 | MAPT (0.46) | NR2E1MAPTMEN1KMT2ATP53 | |
| SCHEMBL2205874 | 0.84 | NR2E1 (0.44) | NR2E1MAPTMEN1KMT2ATP53 | |
| SCHEMBL2202372 | 0.81 | KDR (0.47) | MAPTMEN1KMT2ATP53ROCK2 | |
| SCHEMBL2203641 | 0.80 | RORC (0.51) | MAPTMEN1KMT2ATP53ROCK2 | |
| SCHEMBL2202953 | 0.80 | NR2E1 (0.46) | NR2E1MAPTMEN1KMT2ATP53 | |
| SCHEMBL1408502 | 0.79 | AURKA (0.55) | MAPTMEN1KMT2ATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | claimed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| CN-101558068-A | Phenylacetamides useful as protein kinase inhibitors | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| CN-101558068-A | Phenylacetamides useful as protein kinase inhibitors | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | MCHR1 4624/4885NR2E1 2504/4885MAPT 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.